


Bexarotene-d₄

Cat. No.:	HY-14171S		
CAS No.:	2182068-00-2		
Molecular Formula:	C ₂₄ H ₂₄ D ₄ O ₂		
Molecular Weight:	352.5		
Target:	RAR/RXR; Autophagy		
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor; Autophagy		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description

Bexarotene-d₄ is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].

REFERENCES

- [1]. Vakeva L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. *Acta Derm Venereol.* 2012 May;92(3):258-63. doi: 10.2340/00015555-1359.
- [2]. Gui Y, et al. Bexarotene attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1. *J Pain.* 2019 Jan 17. pii: S1526-5900(18)30607-2.
- [3]. Zhang X, Schlaak M, Fabri M, Mauch C, Kurschat P. Successful Treatment of a Panniculitis-Like Primary Cutaneous T-Cell Lymphoma of the α/β Type with Bexarotene. *Case Rep Dermatol.* 2012 Jan;4(1):56-60.
- [4]. Orendas P, Kubatka P, Kajo K, Stollarova N, Kassayova M, Bojkova B, Pec M, Nosal V, Kiskova T, Zihlavnikova K, Karsnakova R. Melatonin enhanced bexarotene efficacy in experimental mammary carcinogenesis. *Neoplasma.* 2012;59(4):469-74.
- [5]. Cras A, Politis B, Balitrand N, Darsin-Bettinger D, Boelle PY, Cassinat B, Toubert ME, Chomienne C.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA